New psychoactive substances: Pharmacology influencing UK practice, policy and the law

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA

(2018) Thomas F. Gamage et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Assessing the role of dopamine in the differential neurotoxicity patterns of methamphetamine, mephedrone, methcathinone and 4-methylmethamphetamine

(2018) John H. Anneken et al.   NEUROPHARMACOLOGY

New ACMD regulations threaten UK's pharmaceutical discovery

(2017) David Nutt   LANCET

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal

(2016) Ziva D. Cooper   Current Psychiatry Reports

Contribution of serotonin and dopamine to changes in core body temperature and locomotor activity in rats following repeated administration of mephedrone

(2015) Sinead E. Shortall et al.   ADDICTION BIOLOGY

Recreational nitrous oxide use: Prevalence and risks

(2015) Jan van Amsterdam et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

The preclinical pharmacology of mephedrone; not just MDMA by another name

(2014) A R Green et al.   BRITISH JOURNAL OF PHARMACOLOGY

Deaths from “legal highs”: a problem of definitions

(2014) Leslie A King et al.   LANCET

Effects of Subanesthetic Dose of Nitrous Oxide on Cerebral Blood Flow and Metabolism

(2013) Naranjargal Dashdorj et al.   ANESTHESIOLOGY

Suspected and Confirmed Fatalities Associated With Mephedrone (4-Methylmethcathinone, “Meow Meow”) in the United Kingdom

(2012) Fabrizio Schifano et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Beyond THC: The New Generation of Cannabinoid Designer Drugs

(2011) Liana Fattore et al.   Frontiers in Behavioral Neuroscience